I don't agree here. Ataluren isn't in preclinical stage or early clinical stage currently, it has ph2b and ph3 data from two leading indications, which showed it didn't work or at least didn't work that well in the two indications IMO. So, you can't accuse anyone hiding preclinical data at this point. If investors couldn't evaluate the drug correctly based on large volume of clinical data, they couldn't evaluate it correctly based on preclinical data either.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.